◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocksARWR › Free Cash Flow

Arrowhead Pharmaceuticals Inc (ARWR) Free Cash Flow 2006–TTM

DATA UPDATED 2026-09-19

Arrowhead Pharmaceuticals Inc annual free cash flow for fiscal TTM was -$75 million, compared with $157 million in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

ARWR Annual Free Cash Flow

Free Cash Flow (annual)TTM → 2026-06-302025-09-302024-09-302023-09-302022-09-302021-09-302020-09-302019-09-302018-09-302017-09-302016-09-302015-09-302014-09-302013-09-302012-09-302011-09-302010-09-302009-09-302008-09-302007-09-302006-09-30
Free Cash Flow (FCF)($75M)$157M($604M)($331M)($189M)$148M($108M)$161M($49M)($32M)($68M)($68M)($37M)($19M)($16M)($5M)($8M)($15M)($28M)($25M)($16M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ARWR Quarterly Free Cash Flow

Free Cash Flow (quarterly)2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-30
Free Cash Flow (FCF)($181M)$82M$11M$13M($157M)$455M($154M)($162M)($130M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Free Cash Flow at Comparable Companies

More ARWR metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · EBITDA · Shares Outstanding

All ARWR financial statements → Interactive ARWR charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.